BRPI0415766A - uso de selecionados complexos zinco-aminoácido como anti-malarial - Google Patents

uso de selecionados complexos zinco-aminoácido como anti-malarial

Info

Publication number
BRPI0415766A
BRPI0415766A BRPI0415766-4A BRPI0415766A BRPI0415766A BR PI0415766 A BRPI0415766 A BR PI0415766A BR PI0415766 A BRPI0415766 A BR PI0415766A BR PI0415766 A BRPI0415766 A BR PI0415766A
Authority
BR
Brazil
Prior art keywords
compound
zinc
w2mef
malarial
amino acid
Prior art date
Application number
BRPI0415766-4A
Other languages
English (en)
Inventor
Pawan Malhotra
Venkata Naga Dasara Palakodeti
Asif Mohammed
Jamal Hossain Manzar
Sunil Mukherji
Venkatasamy Manivel
Kanury Venkata Subba Rao
Gyan Chandra Mishra
Subrayan Perunnina Parmeswaran
Anil Chatterji
Original Assignee
Council Of Scientifc & Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Of Scientifc & Ind Res filed Critical Council Of Scientifc & Ind Res
Publication of BRPI0415766A publication Critical patent/BRPI0415766A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE SELECIONADOS COMPLEXOS ZINCO-AMINOáCIDO COMO ANTI-MALARIAL". A invenção proporciona o uso de complexos zinco de selecionados aminoácidos provenientes de isómeros D ou L de prolina, lisina, histidina, glicina, arginina e triptofano ou de seus vários derivados hidroxílicos, amino, alquílicos e carboxílicos e cloreto de zinco, acetato de zinco ou outros sais de zinco farmaceuticamente aceitáveis. O uso do composto compreende administrar uma quantidade eficaz dos referidos compostos para a inibição do crescimento do para sita malarial, Plasmodium falciparum. O composto é letal ao parasita em culturas RBC mas não tem efeito sobre RBCS. O composto também possui visível atividade contra a linhagem W2Mef resistente à cloroquina. As curvas dose-resposta para ambas as linhagens 3D7 e W2Mef são idênticas o que sugere fortemente que o composto é igualmente eficaz contra isolados de campo do cloroquino-resistente, P.falciparum. O composto atua sobre a linhagem W2Mef pelo aniquilamento do alvo.
BRPI0415766-4A 2003-10-22 2004-07-19 uso de selecionados complexos zinco-aminoácido como anti-malarial BRPI0415766A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51277803P 2003-10-22 2003-10-22
PCT/IB2004/002320 WO2005039557A1 (en) 2003-10-22 2004-07-19 Use of selected amino acid-zinc complexes as anti-malarial

Publications (1)

Publication Number Publication Date
BRPI0415766A true BRPI0415766A (pt) 2006-12-26

Family

ID=34520058

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415766-4A BRPI0415766A (pt) 2003-10-22 2004-07-19 uso de selecionados complexos zinco-aminoácido como anti-malarial

Country Status (6)

Country Link
US (1) US20050090480A1 (pt)
CN (1) CN1901896B (pt)
BR (1) BRPI0415766A (pt)
TR (1) TR200603675T2 (pt)
WO (1) WO2005039557A1 (pt)
ZA (1) ZA200603215B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171063A1 (en) * 2003-10-20 2005-08-04 Pawan Malhotra Use of phosphono derivatives as anti-malarials
AU2011202542A1 (en) 2010-07-14 2012-02-02 Indian Institute Of Science Benzothiophene carboxamide compounds, composition and applications thereof
WO2014134701A1 (en) * 2013-03-07 2014-09-12 Kane Biotech Inc. Antimicrobial-antibiofilm compositions and methods of use thereof
KR102094182B1 (ko) * 2018-06-28 2020-03-30 주식회사 알랙스탠드 아연 함유 수용성 폴리글루타믹산 복합체 조성물
KR102498802B1 (ko) * 2019-09-24 2023-02-10 고려대학교 세종산학협력단 후코이단을 유효성분으로 포함하는 말라리아 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
US5659023A (en) * 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
US6558710B1 (en) * 1999-06-14 2003-05-06 Helen Rebecca Godfrey Topical zinc compositions and methods of use
DE10008522A1 (de) * 2000-02-24 2001-09-06 Hassan Jomaa Verwendung von 2-PHenylendiaminderivaten zur Behandlung von Infektionen
US6326023B1 (en) * 2000-03-28 2001-12-04 Council Of Scientific & Industrial Research Synergistic anti-malarial formulation

Also Published As

Publication number Publication date
TR200603675T2 (tr) 2007-01-22
ZA200603215B (en) 2007-11-28
CN1901896B (zh) 2011-04-20
US20050090480A1 (en) 2005-04-28
WO2005039557A1 (en) 2005-05-06
CN1901896A (zh) 2007-01-24

Similar Documents

Publication Publication Date Title
Gottardi et al. N-chlorotaurine, a natural antiseptic with outstanding tolerability
JP5474276B2 (ja) 高脂血症治療剤
BR112012029959A2 (pt) compostos de carbamato de mentila como ativos para clareamento de pele e/ou cabelo
BRPI0510414A (pt) uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
NI201100209A (es) DERIVADOS DE 1H - IMIDAZOL [ 4, 5 - c ] QUINOLINONA
BRPI0409211A (pt) composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
RU2009101326A (ru) Препарат для наружного применения на кожу, содержащий тритерпеновую кислоту
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
EA200501105A1 (ru) Фармацевтическая композиция
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
BRPI0916282B8 (pt) uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica
TR200002969T2 (tr) Farmasötik bileşim.
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
JP2012505905A5 (pt)
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
BRPI0415766A (pt) uso de selecionados complexos zinco-aminoácido como anti-malarial
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
JP2017525738A5 (pt)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2315 DE 19-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.